Advertisement Redpoint Bio wins two new US patents for low-sodium salt substitute - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Redpoint Bio wins two new US patents for low-sodium salt substitute

Redpoint Bio, a development-stage biotechnology company, has received two new US patents that cover the compositions and methods for its low-sodium salt substitute called Betrasalt.

According to the company, Betrasalt contains a proprietary formulation of FEMA GRAS materials that mitigates the bitter and metallic taste of potassium chloride (KCl), the active ingredient used in many salt-substitute products.

Redpoint’s Betrasalt formulation is said to retain the cooking functionality and preservative qualities of common table salt (sodium chloride) with an improved taste profile as compared to KCl alone.

Raymond Salemme, CEO of Redpoint Bio, said: “Excess dietary salt is thought to be a contributor to hypertension and associated cardiovascular diseases that are linked to high morbidity and increased healthcare costs. Redpoint is actively seeking potential partners interested in commercializing the Betrasalt technology.”